This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2012
  • /
  • 05
  • /
  • BOLERO-2 study update for Afinitor (Novartis) in H...
Drug news

BOLERO-2 study update for Afinitor (Novartis) in HR+ Breast Cancer presented at ASCO

Read time: 1 mins
Last updated:31st May 2012
Published:31st May 2012
Source: Pharmawand
An 18-month analysis from the Phase III BOLERO-2 study from Novartis confirms that Afinitor (everolimus) plus exemestane, an aromatase inhibitor, more than doubled the time postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer lived without tumor growth (progression-free survival; PFS).The updated results show median PFS for everolimus plus exemestane was 7.8 months compared to 3.2 months with hormonal therapy alone (hazard ratio=0.45 [95% confidence interval (CI): 0.36 to 0.54]; p<0.0001) by local investigator assessment and significantly reduced the risk of cancer progression by 55% versus exemestane alone. see piccart m et al. "everolimus for postmenopausal women with advanced breast cancer: updated results of the bolero-2 phase iii trial." abstract #559. american society of clinical oncology 2012 annual meeting, chicago, il>

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.